BR112022022608A2 - Compostos como inibidores de bcl-2 - Google Patents

Compostos como inibidores de bcl-2

Info

Publication number
BR112022022608A2
BR112022022608A2 BR112022022608A BR112022022608A BR112022022608A2 BR 112022022608 A2 BR112022022608 A2 BR 112022022608A2 BR 112022022608 A BR112022022608 A BR 112022022608A BR 112022022608 A BR112022022608 A BR 112022022608A BR 112022022608 A2 BR112022022608 A2 BR 112022022608A2
Authority
BR
Brazil
Prior art keywords
inhibitors
bcl
compounds
compounded
methods
Prior art date
Application number
BR112022022608A
Other languages
English (en)
Inventor
Zhang Weipeng
Liu Hongbin
Tan Rui
Li Zhifu
Rong Yue
Liu Qihong
Chen Zhifang
Chen Ling
Xu Hua
Zhou Zuwen
Yu Jinhua
Tan Haohan
Liu Bin
Wang Yunling
Yang Lijun
Jiang Lihua
He Chengxi
Zhao Xingdong
Lin Shu
Wang Weibo
Original Assignee
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd filed Critical Fochon Pharmaceuticals Ltd
Publication of BR112022022608A2 publication Critical patent/BR112022022608A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO COMO INIBIDORES DE BCL-2. A presente invenção refere-se a certos inibidores de Bcl2, composições farmacêuticas dos mesmos e métodos de uso dos mesmos.
BR112022022608A 2020-05-08 2021-05-07 Compostos como inibidores de bcl-2 BR112022022608A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063021816P 2020-05-08 2020-05-08
US202063115471P 2020-11-18 2020-11-18
US202163146601P 2021-02-06 2021-02-06
PCT/CN2021/092104 WO2021223736A1 (en) 2020-05-08 2021-05-07 Compounds as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
BR112022022608A2 true BR112022022608A2 (pt) 2023-05-02

Family

ID=78468646

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022608A BR112022022608A2 (pt) 2020-05-08 2021-05-07 Compostos como inibidores de bcl-2

Country Status (11)

Country Link
US (1) US20230159527A1 (pt)
EP (1) EP4146649A4 (pt)
JP (1) JP2023525748A (pt)
KR (1) KR20230051125A (pt)
CN (1) CN115843297A (pt)
AU (1) AU2021268845A1 (pt)
BR (1) BR112022022608A2 (pt)
CA (1) CA3177906A1 (pt)
MX (1) MX2022014007A (pt)
TW (1) TW202200576A (pt)
WO (1) WO2021223736A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089463A1 (zh) * 2020-10-28 2022-05-05 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
WO2022143602A1 (en) * 2020-12-28 2022-07-07 Ascentage Pharma (Suzhou) Co., Ltd. Methods of treating multiple sclerosis
WO2022218311A1 (en) * 2021-04-13 2022-10-20 Appicine Therapeutics (Hk) Limited Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof
EP4433478A1 (en) * 2021-11-20 2024-09-25 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors
CN116217566A (zh) * 2021-12-06 2023-06-06 杭州和正医药有限公司 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
WO2023231777A1 (en) * 2022-06-01 2023-12-07 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2693107T3 (es) * 2011-01-25 2018-12-07 The Regents Of The University Of Michigan Inhibidores de Bcl-2/Bcl-xL para su uso en el tratamiento del cáncer
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
BR112020022092A2 (pt) * 2018-04-29 2021-02-02 Beigene, Ltd. compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica
WO2020140005A2 (en) * 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20230002369A1 (en) * 2019-10-28 2023-01-05 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Also Published As

Publication number Publication date
KR20230051125A (ko) 2023-04-17
CA3177906A1 (en) 2021-11-11
JP2023525748A (ja) 2023-06-19
EP4146649A4 (en) 2024-09-11
MX2022014007A (es) 2023-02-09
US20230159527A1 (en) 2023-05-25
EP4146649A1 (en) 2023-03-15
WO2021223736A1 (en) 2021-11-11
AU2021268845A1 (en) 2023-01-05
TW202200576A (zh) 2022-01-01
CN115843297A (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
BR112022022608A2 (pt) Compostos como inibidores de bcl-2
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
CO2022003782A2 (es) Inhibidores de kras g12d
BR112021019748A2 (pt) Degradadores de stat e usos dos mesmos
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
BR112018003812A2 (pt) compostos de heteroarila como inibidores de irak e usos dos mesmos
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
BR112015028171A8 (pt) Inibidores de acc e seu uso
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
BR112023023223A2 (pt) Degradadores de cdk2 e usos dos mesmos
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112021011325A2 (pt) Derivados de rapamicina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FOCHON BIOSCIENCES, LTD. (CN)